- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055322
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
May 11, 2026 updated by: Texas Tech University
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD: Adapting, Implementing, and Evaluating Dialectical Behavior Therapy Skills Training Interventions
This project aims to adapt, implement, and evaluate a Dialectical Behavior Therapy skills training group intervention for aging adult family caregivers of person with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) to reduce suicidality.
By adapting this modality, the investigators will provide a scalable intervention tailored for this high-risk population, maximizing the public health impact and improving suicide prevention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Family caregivers of persons with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) experience caregiving-related distress and have about 650% higher rates of suicide ideation (SI; 32.32%) compared to the general population (4.3%).
Dialectical Behavior Therapy (DBT), an evidence-based intervention for suicide, addresses multiple areas of psychosocial functioning.
Standard DBT is often too re-source-intensive (6 months to 1 year of weekly individual sessions and 1.5-2.5-hour
weekly skills training group sessions) and is not tailored to family caregivers of persons with AD/ADRD with SI, creating a significant barrier to SI treatment.
The investigators will develop, implement, and evaluate an adapted DBT skills training groups tailored to the unique experiences and needs of family caregivers of persons with AD/ADRD to reduce suicide-related out-comes most effectively.
Our specific aims are: (1) Adapt DBT skills groups for family caregivers (of persons with AD/ADRD) endorsing direct or indirect SI (directly stated SI vs. indirect indicators of SI) to ensure it applies to direct and indirect SI and considers SI underreporting; (2) Evaluate the feasibility, acceptability, and fidelity of the adapted DBT skills groups in this sample; (3) Assess preliminary effectiveness indicators of the adapted DBT skills groups.
For Aim 1, a panel of experts and two stakeholders (Garrison Institute on Aging (GIA) staff; family caregivers of a person with AD/ADRD), will inform the adaptation of DBT skills training to family caregiv-ers of persons with AD/ADRD and shorten to 16 weekly, 1-hour skills groups sessions, over 4 months.
For Aims 2 and 3, the investigators will implement the adapted DBT skills training groups among family caregivers of persons with AD/ADRD with direct/indirect SI at screening while providing respite, all at GIA.
The investigators will collect relevant demo-graphic data from family caregivers and family caregiver-reported data about the person with AD/ADRD.
Over 18 time points (baseline, following weekly DBT sessions, follow-up), participants will complete self-report assessments targeting DBT fidelity/acceptably, SI (direct and indirect), and suicide risk correlates.
The investigators will also record DBT session to monitor fidelity.
The investigators will track participant recruitment, group attendance, retention as feasibility metrics.
The investigators will also use innovative methodology by collecting inflammation biomarkers and heart rate variability data as an indirect SI assessment.
Lastly, the investigators will conduct focus groups after the intervention for addi-tional qualitative acceptability and feasibility data.
The investigators will also survey GIA site staff to evaluate their perceived acceptability and feasibility of the intervention at GIA.
Our hypotheses are that 1) our adapted DBT skills group will be feasible, acceptable, and maintain DBT fidelity, and 2) SI (direct and indirect), suicide risk factors, and inflammation will decrease, and heart rate variability will increase post intervention.
Our expected outcomes are to have a scalable DBT group intervention for family caregivers of persons with ADRD, indications of feasibility and acceptability, and preliminary effectiveness indicators.
This work will provide a life-saving suicide prevention approach for family caregivers of persons with AD/ADRD, provide students with multidisciplinary research experiences, and significantly strengthen our university research environment.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79413
- Garrison Institute on Aging
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- being age 50 and over (as most informal caregivers of persons with AD/ADRD are 50 or older; AARP, 2020; Chi et al., 2019)
- being the primary informal caregiver
- living with an AD/ADRD-diagnosed patient
- being willing to be prodded for bloodspots
- demonstrating English-fluency
- endorsing a direct or indirect SI/suicide risk
- Eligible individuals will score above clinical cutoffs for SI/suicide risk on at least 1 of 3 measures: the Suicide Behavior Questionnaire-R (SBQ-R; score > 6; Osman et al., 2002), Interpersonal Needs Question-naire (INQ; thwarted belonging score > 35; and perceived burden > 17; Mitchell et al., 2020) or the Geriatric De-pression Scale (GDS; score > 5 Heisel et al., 2005).
Exclusion Criteria:
• Participants with neurocognitive impairment will be excluded (a Mini-Mental State Exam score ≤ 23; Folstein et al., 1975; Kochhann et al., 2010)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adapted Dialectical Behavior Therapy
Adapting Dialectical Behavior Therapy to focus on reducing suicide ideation for family caregivers of persons with AD/ADRD
|
DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Suicide Cognitions Scale-Revised (SCS-R)
Time Frame: All 18 timepoints
|
The SCS-R is a 16-item self-report measure that assesses a variety of beliefs, attitudes, expectations, and perceptions associated with the emergence of suicidal thoughts.
Importantly, the SCS-R does not directly ask about suicidal thoughts or behaviors, making it an indirect suicide ideation assessment.
Previous studies have found that the SCS-R demonstrates excellent internal consistency (α = .96-.98; Bryan et al., 2021; Moscardini et al., 2020).
|
All 18 timepoints
|
|
Beck Scale for Suicide Ideation (BSSI)
Time Frame: through study completion, an average of 6 months
|
The BSSI is a 21-item self-report measure with 19 items to evaluate the current intensity of patients' specific attitudes, behaviors, and plans for suicide, including desire for suicide (suicide ideation) and desire for death generally (death ideation).
Two items also assess suicide attempt history and intent during the most recent suicide attempt (if applicable).
The BSSI has demonstrated good psychometric properties and has good predictive validity for suicide death (Beck et al., 1997; Brown et al., 2000), including among aging adults (Witte et al., 2006).
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interpersonal Needs Questionnaire (INQ)
Time Frame: through study completion, an average of 6 months
|
The INQ is a 15-item self-report assessment of thwarted belonging (9 items; scores range from 9 to 63) and perceived burden (6 items; scores range from 6 to 42).
The INQ has demonstrated strong psychometric properties, including construct validity among psychiatric outpatients and aging adults (Hill et al., 2015; Van Orden et al., 2012) and strong internal consistency thwarted belonging (.91) and perceived burden (.94; Mitchell et al., 2020).
|
through study completion, an average of 6 months
|
|
Geriatric Depression Scale (GDS)
Time Frame: through study completion, an average of 6 months
|
The GDS-15 is a 15-item self-report measure of depression, includes a 5-item subscale to assess for suicide ideation, and has been used as a screener for suicide ideation (Cheng et al., 2010).
The GDS has been found to have good internal consistency when used with informal caregivers of patients with AD/ADRD (α = .73).
|
through study completion, an average of 6 months
|
|
Difficulty in Emotion Regulation Scale (DERS)
Time Frame: through study completion, an average of 6 months
|
The DERS is an 18-item, six-subscale self-report measure of emotion regulation.
The subscales assess respondents' acceptance of emotions, ability to engage in goal-directed behavior when distressed, impulse control, awareness of emotions, access to strategies for regulation, and clarity of emotions.
The DERS-18 subscales have demonstrated good internal consistency (α = .77-.90).
|
through study completion, an average of 6 months
|
|
The Distress Tolerance Scale (DTS)
Time Frame: through study completion, an average of 6 months
|
The DTS is a 15-item self-report measure of the degree to which individuals experience negative emotions as intolerable.
The DTS has demonstrated good internal consistency (α = .91;
Anestis et al., 2007).
|
through study completion, an average of 6 months
|
|
Interpersonal Sensitivity Scale (INT)
Time Frame: through study completion, an average of 6 months
|
The INT is a 10-item self-report measure that assesses participants' abilities to manage relationships via processes associated with interpersonal effectiveness.
The INT has demonstrated good internal consistency (α = .91;
Lenz et al., 2016).
|
through study completion, an average of 6 months
|
|
The Mindful Attention Awareness Scale (MAAS)
Time Frame: through study completion, an average of 6 months
|
The MAAS is a 15-item single-dimension self-report measure of trait mindfulness, measuring the frequency of open and receptive attention to and awareness of ongoing events and experience.
MAAS has demonstrated good internal consistency (α = .89-.93; Black et al., 2012), including among aging adults (e.g., Mally & Fiocco, 2016).
|
through study completion, an average of 6 months
|
|
DBT Acceptability Measure
Time Frame: through study completion, an average of 6 months
|
This is an 8-item self-report measure assessing participants' perceived acceptability of DBT (e.g., I would participate in this intervention again).
Questions are analyzed separately to indicate acceptability of the adapted DBT manual.
|
through study completion, an average of 6 months
|
|
Zarit Burden Interview (ZBI)
Time Frame: through study completion, an average of 6 months
|
The ZBI is a 22-item self-report measure of caregiver burden.
It has been validated with informal caregivers of patients with AD/ADRD and has been shown to have good internal consistency (0.83-0.92;
Hebert et al., 2000; Bedard et al., 2001) and validity (Hebert et al., 2000).
|
through study completion, an average of 6 months
|
|
Short Form Health Survey (SF-12)
Time Frame: through study completion, an average of 6 months
|
The SF-12 is a 12-item self-report measure of health and has been validated with aging adults (Jakobsson, 2006).
The SF-12 is a commonly used instrument to measure health-related quality of life at various ages.
The SF-12 has been shown to be psychometrically valid and reliable (Ware et al., 1996; Ware et al., 1997).
|
through study completion, an average of 6 months
|
|
Heart Rate Variability (HRV)
Time Frame: through study completion, an average of 6 months
|
HRV will be evaluated using Empatica E4 bands, providing autonomic nervous system arousal data, including heart rate.
HRV has been used with aging adults and with informal caregivers in past studies (e.g., Brown et al., 2018; James et al., 2021).
|
through study completion, an average of 6 months
|
|
Inflammation Markers
Time Frame: through study completion, an average of 6 months
|
CRP and IL-6, Blood for analysis will be collected on filter paper (dried blood spots) Dried blood spots are a non-invasive and low-cost method of collecting blood that involves a finger prick with a lancet and blotting the blood onto filter paper (Miller)
|
through study completion, an average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 7, 2025
Primary Completion (Actual)
May 1, 2026
Study Completion (Actual)
May 1, 2026
Study Registration Dates
First Submitted
September 12, 2023
First Submitted That Met QC Criteria
September 19, 2023
First Posted (Actual)
September 26, 2023
Study Record Updates
Last Update Posted (Actual)
May 14, 2026
Last Update Submitted That Met QC Criteria
May 11, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Pathologic Processes
- Behavioral Symptoms
- Neurocognitive Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Self-Injurious Behavior
- Stress, Psychological
- Pathological Conditions, Signs and Symptoms
- Behavior
- Caregiver Burden
- Alzheimer Disease
- Suicide
- Depression
- Inflammation
Other Study ID Numbers
- TexasTechU4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The investigators will not be providing any individual participant data.
It will all be aggregate
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Bekelu Teka WorkuJimma UniversityNot yet recruitingPrenatal Depression | Mental Health Related Quality of Life | Maternal Postpartum Depression | Paternal Postpartum DepressionEthiopia
Clinical Trials on Adapted Dialectical Behavior Therapy
-
ArkinRecruitingPTSD | Substance Abuse | Emotion Regulation DisordersNetherlands
-
Weill Medical College of Cornell UniversityGreen Chimneys Residential Treatment Center, Brewster, NYCompletedChildhood AggressionUnited States
-
University Hospital, Strasbourg, FranceRecruitingEncephalitis | Meningitis | Acquired Brain Injury | Cerebral Anoxia | Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic) | Brain Tumor (After Recovery)France
-
University of WindsorRecruitingDepression | Mood Disorders | Stress | Anxiety | Depression - Major Depressive DisorderCanada
-
University Hospital, Strasbourg, FranceCompletedAutism Spectrum DisordersFrance
-
Dr. Jessica JonesProvidence CareCompletedIntellectual DisabilityCanada
-
Pontificia Universidad Catolica de ChileUniversity Diego PortalesNot yet recruitingBorderline Personality DisorderChile
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedSuicide | Post-traumatic Stress Disorder | Self-injurious BehaviorUnited States
-
Fordham UniversityNot yet recruitingAntisocial Personality DisorderUnited States
-
Rutgers, The State University of New JerseyCompletedBorderline Personality DisorderUnited States